2016 Q1 Form 10-K Financial Statement

#000106282216000051 Filed on March 11, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2014 Q4 2014 Q3
Revenue $12.49M $21.48M $419.0K
YoY Change 597.21% 1423.55% 76.05%
Cost Of Revenue $0.00
YoY Change
Gross Profit $12.49M
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $8.398M $4.000M $4.500M
YoY Change 47.33% 17.65% -4.26%
% of Gross Profit 67.22%
Research & Development $37.00M $20.00M $24.11M
YoY Change 77.34% -1.48% -5.09%
% of Gross Profit 296.16%
Depreciation & Amortization $521.0K $200.0K $500.0K
YoY Change 46.76% -71.43% -16.67%
% of Gross Profit 4.17%
Operating Expenses $46.37M $24.90M $40.76M
YoY Change 63.72% 35.33% 29.57%
Operating Profit -$33.87M -$3.447M -$40.34M
YoY Change 27.69% -79.69% 29.22%
Interest Expense $1.649M -$900.0K $449.0K
YoY Change -3.11% 80.0% -8.74%
% of Operating Profit
Other Income/Expense, Net $637.0K $1.300M $287.0K
YoY Change 316.34% 2509.09%
Pretax Income -$34.88M -$3.000M -$40.50M
YoY Change 24.14% -82.76% 27.76%
Income Tax -$100.0K $0.00
% Of Pretax Income
Net Earnings -$34.88M -$2.933M -$40.50M
YoY Change 24.24% -83.16% 27.92%
Net Earnings / Revenue -279.2% -13.65% -9665.39%
Basic Earnings Per Share
Diluted Earnings Per Share -$336.5K -$34.16K -$551.0K
COMMON SHARES
Basic Shares Outstanding 103.8M shares 514.8M shares 514.8M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $477.1M $338.9M $57.40M
YoY Change 51.6% 163.33% -61.94%
Cash & Equivalents $24.68M $137.3M $26.78M
Short-Term Investments $452.5M $201.6M $30.70M
Other Short-Term Assets $14.27M $4.764M $5.937M
YoY Change 346.81% 2.76% -18.19%
Inventory
Prepaid Expenses
Receivables $741.0K $1.035M $165.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $492.2M $369.0M $87.82M
YoY Change 43.78% 174.23% -44.89%
LONG-TERM ASSETS
Property, Plant & Equipment $20.75M $1.080M $1.494M
YoY Change 2735.11% -97.39% -96.43%
Goodwill $44.54M $44.54M $44.54M
YoY Change 0.0% 0.0% 0.0%
Intangibles $53.36M $53.36M $53.56M
YoY Change 0.0% -0.37% 0.0%
Long-Term Investments
YoY Change
Other Assets $530.0K $3.409M $108.0K
YoY Change -85.83% 2267.36% -31.65%
Total Long-Term Assets $119.2M $102.4M $99.70M
YoY Change 16.42% -26.66% -28.83%
TOTAL ASSETS
Total Short-Term Assets $492.2M $369.0M $87.82M
Total Long-Term Assets $119.2M $102.4M $99.70M
Total Assets $611.3M $471.4M $187.5M
YoY Change 37.48% 71.93% -37.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $25.54M $13.06M $9.741M
YoY Change 110.38% 34.47% 0.33%
Accrued Expenses $23.62M $10.12M $13.13M
YoY Change 100.65% 31.87% 13.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.020M $20.17M $20.61M
YoY Change -89.75% 1079.36% 1130.39%
Total Short-Term Liabilities $121.9M $44.97M $44.27M
YoY Change 165.48% 133.07% 87.6%
LONG-TERM LIABILITIES
Long-Term Debt $100.6M $87.50M $0.00
YoY Change 14.91% 333.88% -100.0%
Other Long-Term Liabilities $14.59M $23.54M $34.01M
YoY Change -37.26% -27.33% -9.06%
Total Long-Term Liabilities $115.1M $111.0M $34.01M
YoY Change 3.96% 111.28% -41.37%
TOTAL LIABILITIES
Total Short-Term Liabilities $121.9M $44.97M $44.27M
Total Long-Term Liabilities $115.1M $111.0M $34.01M
Total Liabilities $358.5M $187.4M $109.7M
YoY Change 91.61% 80.16% -3.56%
SHAREHOLDERS EQUITY
Retained Earnings -$1.144B -$1.104B -$1.101B
YoY Change 1.01% 9.99% 11.63%
Common Stock $104.0K $104.0K $516.0K
YoY Change -85.69% -79.77% 0.39%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.368M $2.390M $2.390M
YoY Change 22.61% 59.02% 59.02%
Treasury Stock Shares 306.0K shares 183.0K shares 1.281M shares
Shareholders Equity $252.9M $284.0M $77.82M
YoY Change
Total Liabilities & Shareholders Equity $611.3M $471.4M $187.5M
YoY Change 37.48% 71.93% -37.38%

Cashflow Statement

Concept 2016 Q1 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$34.88M -$2.933M -$40.50M
YoY Change 24.24% -83.16% 27.92%
Depreciation, Depletion And Amortization $521.0K $200.0K $500.0K
YoY Change 46.76% -71.43% -16.67%
Cash From Operating Activities -$43.74M -$4.400M -$21.20M
YoY Change 86.25% -79.82% -11.3%
INVESTING ACTIVITIES
Capital Expenditures $54.00K -$100.0K $0.00
YoY Change 217.65% -50.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$133.6M -$170.6M $20.50M
YoY Change 88.17% -526.5% 0.0%
Cash From Investing Activities -$133.6M -$170.7M $20.50M
YoY Change 88.25% -529.97% 0.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $437.0K
YoY Change 22.41%
Debt Paid & Issued, Net $491.0K
YoY Change 7.68%
Cash From Financing Activities -$928.0K 285.7M -300.0K
YoY Change 11.81% -285800.0%
NET CHANGE
Cash From Operating Activities -$43.74M -4.400M -21.20M
Cash From Investing Activities -$133.6M -170.7M 20.50M
Cash From Financing Activities -$928.0K 285.7M -300.0K
Net Change In Cash -$178.3M 110.6M -1.000M
YoY Change 87.09% 521.35% -72.22%
FREE CASH FLOW
Cash From Operating Activities -$43.74M -$4.400M -$21.20M
Capital Expenditures $54.00K -$100.0K $0.00
Free Cash Flow -$43.79M -$4.300M -$21.20M
YoY Change 86.34% -80.09% -10.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001062822
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
103769656 shares
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q2 dei Entity Public Float
EntityPublicFloat
335000000 USD
CY2015 dei Entity Registrant Name
EntityRegistrantName
LEXICON PHARMACEUTICALS, INC./DE
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014Q4 lxrx Accumulated Depreciation Reclassified To Held For Sale
AccumulatedDepreciationReclassifiedToHeldForSale
38000000 USD
CY2015Q4 lxrx Buildings Collateral
BuildingsCollateral
59100000 USD
CY2014Q4 lxrx Buildings Reclassified To Held For Sale
BuildingsReclassifiedToHeldForSale
59100000 USD
CY2013 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
-2210000 USD
CY2014 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
1428000 USD
CY2015 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
5927000 USD
CY2001Q3 lxrx Coelacanth Goodwill
CoelacanthGoodwill
25800000 USD
CY2001Q3 lxrx Coelacanth Purchase Price
CoelacanthPurchasePrice
36000000 USD
CY2015Q2 lxrx Common Stock Shares Authorized After Reverse Stock Split
CommonStockSharesAuthorizedAfterReverseStockSplit
225000000 shares
CY2015Q2 lxrx Common Stock Shares Authorized Before Reverse Stock Split
CommonStockSharesAuthorizedBeforeReverseStockSplit
900000000 shares
CY2015Q4 lxrx Convertible Debt Instrument Interest Rate Stated Percentage
ConvertibleDebtInstrumentInterestRateStatedPercentage
0.0525
CY2014Q4 lxrx Deferred Tax Liability Related To Acquisition Of Symphony Icon
DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
-18675000 USD
CY2015Q4 lxrx Deferred Tax Liability Related To Acquisition Of Symphony Icon
DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
-18675000 USD
CY2015Q4 lxrx Directors Annual Option Grant
DirectorsAnnualOptionGrant
2857 shares
CY2015Q4 lxrx Directors Annual Restricted Stock Award Value
DirectorsAnnualRestrictedStockAwardValue
20000 USD
CY2015Q4 lxrx Directors Intial Option Grant
DirectorsIntialOptionGrant
4285 shares
CY2013 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
1.00
CY2014 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
0.06
CY2015 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
0.01
CY2014 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributedto France
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance
0.94
CY2015 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributedto France
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance
0.99
CY2014 lxrx Entity Wide Revenue Ipsen Percentage
EntityWideRevenueIpsenPercentage
0.94
CY2013 lxrx Entity Wide Revenue Mc Nair Medical Institute Percentage
EntityWideRevenueMcNairMedicalInstitutePercentage
0.57
CY2015 lxrx Entity Wide Revenue Sanofi Percentage
EntityWideRevenueSanofiPercentage
0.98
CY2013 lxrx Entity Wide Revenue Taconic Farms Percentage
EntityWideRevenueTaconicFarmsPercentage
0.33
CY2014Q4 lxrx Fair Valueof Assetstobe Sold
FairValueofAssetstobeSold
23800000 USD
CY2015Q4 lxrx Fair Valueof Assetstobe Sold
FairValueofAssetstobeSold
20300000 USD
CY2007Q2 lxrx Holdings Contribution To Icon
HoldingsContributionToIcon
45000000 USD
CY2014Q4 lxrx Ipsen Maximum Regulatory And Commercial Milestones
IpsenMaximumRegulatoryAndCommercialMilestones
34000000 USD
CY2014Q4 lxrx Ipsen Maximum Sales Milestones
IpsenMaximumSalesMilestones
72000000 EUR
CY2014Q4 lxrx Ipsen Revenue Allocatedto Committee Deliverable
IpsenRevenueAllocatedtoCommitteeDeliverable
100000 USD
CY2014Q4 lxrx Ipsen Revenue Allocatedto Development Deliverable
IpsenRevenueAllocatedtoDevelopmentDeliverable
1700000 USD
CY2014Q4 lxrx Ipsen Revenue Allocatedto License Deliverable
IpsenRevenueAllocatedtoLicenseDeliverable
21200000 USD
CY2015 lxrx Ipsen Revenue Recognized
IpsenRevenueRecognized
21400000 USD
CY2014Q4 lxrx Ipsen Total Upfront Payments
IpsenTotalUpfrontPayments
24500000 USD
CY2015Q4 lxrx Land Collateral
LandCollateral
2700000 USD
CY2014Q4 lxrx Land Reclassified To Held For Sale
LandReclassifiedToHeldForSale
2700000 USD
CY2010Q3 lxrx Lexicon Paid Holdings Cash
LexiconPaidHoldingsCash
10000000 USD
CY2007Q2 lxrx Lexicon Received Cash From Holdings
LexiconReceivedCashFromHoldings
15000000 USD
CY2007Q2 lxrx Lexicon Sold Shares To Holdings
LexiconSoldSharesToHoldings
1092946 shares
CY2015Q4 lxrx Limit On Shares That May Be Issued Other Than Stock Options Or Sars Equity Incentive Plan
LimitOnSharesThatMayBeIssuedOtherThanStockOptionsOrSarsEquityIncentivePlan
3571428 shares
CY2014Q4 lxrx Net Proceeds From Stock Offering
NetProceedsFromStockOffering
201900000 USD
CY2014Q4 lxrx Offering Price Per Share
OfferingPricePerShare
7.035
CY2015Q4 lxrx Options Outstanding Equity Incentive Plan
OptionsOutstandingEquityIncentivePlan
4046758 shares
CY2015Q4 lxrx Options Outstanding Non Employee Directors Equity Incentive Plan
OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan
169971 shares
CY2014Q4 lxrx Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
3400000 USD
CY2016Q1 lxrx Real Estate Selling Price
RealEstateSellingPrice
21200000 USD
CY2015 lxrx Restricted Stock Purchase Price As Percent Of Value Of Common Stock
RestrictedStockPurchasePriceAsPercentOfValueOfCommonStock
0.85
CY2015Q4 lxrx Restricted Stock Units Outstanding Equity Incentive Plan
RestrictedStockUnitsOutstandingEquityIncentivePlan
636906 shares
CY2015Q4 lxrx Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount
SanofiCommercializationCostsFundedbyLexiconMaximumAmount
100000000 USD
CY2015Q4 lxrx Sanofi Developmentand Regulatory Milestone Payments
SanofiDevelopmentandRegulatoryMilestonePayments
430000000 USD
CY2015 lxrx Sanofi Revenue Recognized
SanofiRevenueRecognized
126800000 USD
CY2015Q4 lxrx Sanofi Sales Milestone Payments
SanofiSalesMilestonePayments
990000000 USD
CY2015Q4 lxrx Sanofi Upfront Payment
SanofiUpfrontPayment
300000000 USD
CY2013 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
11544 shares
CY2014 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
14651 shares
CY2015 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
21360 shares
CY2013 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue
13.86
CY2014 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue
10.92
CY2015 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriodWeightedAverageGrantDateFairValue
7.49
CY2015Q4 lxrx Sanofi Revenue Allocatedto Development Deliverable
SanofiRevenueAllocatedtoDevelopmentDeliverable
113800000 USD
CY2015Q4 lxrx Sanofi Revenue Allocatedto Funding Deliverable
SanofiRevenueAllocatedtoFundingDeliverable
59400000 USD
CY2015Q4 lxrx Sanofi Revenue Allocatedto License Deliverable
SanofiRevenueAllocatedtoLicenseDeliverable
126800000 USD
CY2014 lxrx Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period
SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriod
8200 shares
CY2014 lxrx Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
11.20
CY2015Q4 lxrx Shares Issued Pursuant To Restricted Stock Awards Non Employee Directors Equity Incentive Plan
SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan
60992 shares
CY2015Q4 lxrx Shares Issued Pursuant To Restricted Stock Units Equity Incentive Plan
SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan
626839 shares
CY2015Q4 lxrx Shares Issued Pursuant To Stock Bonus Awards Equity Incentive Plan
SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan
113940 shares
CY2013 lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
0 USD
CY2014 lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
5750000 USD
CY2015 lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
0 USD
CY2013 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
3045000 USD
CY2014 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
3061000 USD
CY2015 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
3150000 USD
CY2013 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
4376000 USD
CY2014 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
4020000 USD
CY2015 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
3693000 USD
CY2014Q4 lxrx Stock Issued During Period To Invus Shares
StockIssuedDuringPeriodToInvusShares
21321961 shares
CY2015 lxrx Stock Option Exercise Price As Percent Of Value Of Common Stock
StockOptionExercisePriceAsPercentOfValueOfCommonStock
1.00
CY2015Q4 lxrx Stock Options Exercised Equity Incentive Plan
StockOptionsExercisedEquityIncentivePlan
858875 shares
CY2015Q4 lxrx Stock Options Exercised Non Employee Directors Equity Incentive Plan
StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan
0 shares
CY2010Q3 lxrx Symphon Fair Value Of Base And Contingent Payments
SymphonFairValueOfBaseAndContingentPayments
45600000 USD
CY2010Q3 lxrx Symphony Base Payment Discount Rate
SymphonyBasePaymentDiscountRate
0.14
CY2012Q3 lxrx Symphony Base Payment In Shares
SymphonyBasePaymentInShares
1891074 shares
CY2012Q3 lxrx Symphony Base Payment Obligation
SymphonyBasePaymentObligation
35000000 USD
CY2010Q3 lxrx Symphony Contingent Payment Discount Rate
SymphonyContingentPaymentDiscountRate
0.18
CY2014Q4 lxrx Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
5800000 USD
CY2015Q2 lxrx Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
750000 USD
CY2010Q3 lxrx Symphony Contingent Payment Maximum
SymphonyContingentPaymentMaximum
45000000 USD
CY2010Q3 lxrx Symphony Contingent Payment Percentage
SymphonyContingentPaymentPercentage
0.50
CY2014Q4 lxrx Symphony Contingent Payment Total
SymphonyContingentPaymentTotal
11500000 USD
CY2014Q4 lxrx Symphony Contingent Paymentin Shares
SymphonyContingentPaymentinShares
666111 shares
CY2010Q3 lxrx Symphony Icon Goodwill
SymphonyIconGoodwill
18700000 USD
CY2010Q3 lxrx Symphony Payment In Stock Limitation
SymphonyPaymentInStockLimitation
0.50
CY2010Q3 lxrx Symphony Regulatory Approval Payment
SymphonyRegulatoryApprovalPayment
15000000 USD
CY2010Q3 lxrx Symphony Regulatory Approval Percentage Limit
SymphonyRegulatoryApprovalPercentageLimit
0.50
CY2010Q3 lxrx Symphony Regulatory Approval Reduction Percentage
SymphonyRegulatoryApprovalReductionPercentage
0.50
CY2015Q4 lxrx Tigm Maximum Exposure Through Reporting Date
TIGMMaximumExposureThroughReportingDate
6400000 USD
CY2015Q4 lxrx Tigm Maximum Exposure
TigmMaximumExposure
14200000 USD
CY2015Q4 lxrx Tigm Per Job Payment Amount
TigmPerJobPaymentAmount
2415 USD
CY2015Q4 lxrx Total Shares That May Be Issued Equity Incentive Plan
TotalSharesThatMayBeIssuedEquityIncentivePlan
10000000 shares
CY2015Q4 lxrx Total Shares That May Be Issued Non Employee Directors Equity Incentive Plan
TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan
357142 shares
CY2005Q3 lxrx Tx Enterprise Fund Award
TxEnterpriseFundAward
35000000 USD
CY2005Q3 lxrx Tx Enterprise Fund Award To Texas Am University System
TxEnterpriseFundAwardToTexasAmUniversitySystem
15000000 USD
CY2004Q2 lxrx Woodlands Cash Paid
WoodlandsCashPaid
20800000 USD
CY2004Q2 lxrx Woodlands Mortgage
WoodlandsMortgage
34000000 USD
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13064000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
19725000 USD
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1035000 USD
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
911000 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10120000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24757000 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36274000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
59428000 USD
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-63000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-219000 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1390619000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1397646000 USD
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7421000 USD
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7081000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6843000 USD
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
35000 USD
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4000 USD
CY2013 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
100000 USD
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
520000 USD
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2014 us-gaap Asset Impairment Charges
AssetImpairmentCharges
13102000 USD
CY2015 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3597000 USD
CY2014Q4 us-gaap Assets
Assets
471376000 USD
CY2015Q4 us-gaap Assets
Assets
654832000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
368987000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
532400000 USD
CY2014Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
23849000 USD
CY2015Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
0 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30423000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37499000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
137266000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202989000 USD
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7076000 USD
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
99767000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
65723000 USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
128571000 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
104000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
104000 USD
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-104147000 USD
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-100359000 USD
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4838000 USD
CY2013 us-gaap Contracts Revenue
ContractsRevenue
2109000 USD
CY2014 us-gaap Contracts Revenue
ContractsRevenue
22593000 USD
CY2015 us-gaap Contracts Revenue
ContractsRevenue
129728000 USD
CY2015Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
8.442
CY2014Q4 us-gaap Debt Instrument Convertible Conversion Ratio1
DebtInstrumentConvertibleConversionRatio1
118.4553
CY2015Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
154200000 USD
CY2015Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0823
CY2014Q4 us-gaap Debt Issuance Costs
DebtIssuanceCosts
3400000 USD
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
70000 USD
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
-18675000 USD
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
-18675000 USD
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1618000 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
76499000 USD
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
12679000 USD
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
109151000 USD
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4457000 USD
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4363000 USD
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
412423000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
413605000 USD
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
95946000 USD
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
85385000 USD
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
255518000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
263138000 USD
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
455100000 USD
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
8681000 USD
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
8831000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
40173000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
43728000 USD
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7648000 USD
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8160000 USD
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-412423000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-413605000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
-18675000 USD
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
-18675000 USD
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
18675000 USD
CY2015Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
18675000 USD
CY2013 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
511000 USD
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
376000 USD
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
332000 USD
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2863000 USD
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1928000 USD
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
727000 USD
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.42
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.76
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10500000 USD
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-2210000 USD
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1428000 USD
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
5927000 USD
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-11500000 USD
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-750000 USD
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
29920000 USD
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
27710000 USD
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
17638000 USD
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
22815000 USD
CY2013 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 USD
CY2014 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
1631000 USD
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
47000 USD
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17121000 USD
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19411000 USD
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23835000 USD
CY2014Q4 us-gaap Goodwill
Goodwill
44543000 USD
CY2015Q4 us-gaap Goodwill
Goodwill
44543000 USD
CY2013 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2014 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13544000 USD
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
3597000 USD
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-104126000 USD
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-100364000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4682000 USD
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-70000 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3119000 USD
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1266000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-6203000 USD
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-588000 USD
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-457000 USD
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-124000 USD
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
438000 USD
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-697000 USD
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-171353000 USD
CY2013 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-9000 USD
CY2014 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 USD
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-416000 USD
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1713000 USD
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-128000 USD
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5373000 USD
CY2015Q4 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
10365000 shares
CY2015Q4 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1776000 shares
CY2013 us-gaap Interest Expense
InterestExpense
1971000 USD
CY2014 us-gaap Interest Expense
InterestExpense
2253000 USD
CY2015 us-gaap Interest Expense
InterestExpense
6722000 USD
CY2015Q4 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1277000 USD
CY2013 us-gaap Interest Paid Net
InterestPaidNet
1897000 USD
CY2014 us-gaap Interest Paid Net
InterestPaidNet
1761000 USD
CY2015 us-gaap Interest Paid Net
InterestPaidNet
6270000 USD
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
900000 USD
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1000000 USD
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000 USD
CY2014Q4 us-gaap Liabilities
Liabilities
187358000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
368982000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
471376000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
654832000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44969000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
122996000 USD
CY2013 us-gaap Licenses Revenue
LicensesRevenue
113000 USD
CY2014 us-gaap Licenses Revenue
LicensesRevenue
261000 USD
CY2015 us-gaap Licenses Revenue
LicensesRevenue
286000 USD
CY2015Q4 us-gaap Long Term Debt
LongTermDebt
105808000 USD
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
20167000 USD
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2015000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
87500000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2015000 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
0 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 USD
CY2015Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
16293000 USD
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
87500000 USD
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
103793000 USD
CY2015Q4 us-gaap Mortgage Loans On Real Estate Carrying Amount Of Mortgages
MortgageLoansOnRealEstateCarryingAmountOfMortgages
18300000 USD
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1389000 USD
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
283808000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2032000 USD
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
99544000 USD
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108419000 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-117021000 USD
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91079000 USD
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-75622000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
184776000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-104126000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-100294000 USD
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-4682000 USD
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30835000 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26028000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40498000 USD
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2933000 USD
CY2015Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28076000 USD
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26074000 USD
CY2015Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35282000 USD
CY2015Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
86750000 USD
CY2015Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
88027000 USD
CY2013 us-gaap Operating Expenses
OperatingExpenses
104593000 USD
CY2014 us-gaap Operating Expenses
OperatingExpenses
123220000 USD
CY2015 us-gaap Operating Expenses
OperatingExpenses
128546000 USD
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-102371000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-30472000 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26111000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-40336000 USD
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3447000 USD
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-100366000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26527000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26688000 USD
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-33677000 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
88360000 USD
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
1468000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4193000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
512000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
620000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
607000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
595000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
582000 USD
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1277000 USD
CY2015Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
738000000 USD
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4764000 USD
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
10137000 USD
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3409000 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3305000 USD
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-21000 USD
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-65000 USD
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-156000 USD
CY2014Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
53357000 USD
CY2015Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
53357000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23535000 USD
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
14367000 USD
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
216000 USD
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2255000 USD
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
572000 USD
CY2013 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
873000 USD
CY2014 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
887000 USD
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
357000 USD
CY2014Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
600000 USD
CY2013 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
111490000 USD
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1084000 USD
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
202270000 USD
CY2014Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
87500000 USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014 us-gaap Profit Loss
ProfitLoss
-100294000 USD
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
221953000 USD
CY2015 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
326446000 USD
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1721000 USD
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
80000 USD
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
910000 USD
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
114000 USD
CY2013 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2014 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
84135000 USD
CY2015 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2013 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-26000 USD
CY2014 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2015 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
70000 USD
CY2013 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
212625000 USD
CY2014 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
111444000 USD
CY2015 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
210000000 USD
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
130000 USD
CY2015 us-gaap Profit Loss
ProfitLoss
-4682000 USD
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2170000 USD
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
335000 USD
CY2013 us-gaap Profit Loss
ProfitLoss
-104126000 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37354000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
80655000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1080000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21227000 USD
CY2013 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2014 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2015 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2013 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1574000 USD
CY2014 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1710000 USD
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1859000 USD
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
89682000 USD
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
89279000 USD
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95187000 USD
CY2014Q4 us-gaap Restricted Investments
RestrictedInvestments
430000 USD
CY2015Q4 us-gaap Restricted Investments
RestrictedInvestments
0 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1104252000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1108934000 USD
CY2013 us-gaap Revenues
Revenues
2222000 USD
CY2014Q1 us-gaap Revenues
Revenues
277000 USD
CY2014Q2 us-gaap Revenues
Revenues
676000 USD
CY2014Q3 us-gaap Revenues
Revenues
419000 USD
CY2014Q4 us-gaap Revenues
Revenues
21482000 USD
CY2014 us-gaap Revenues
Revenues
22854000 USD
CY2015Q1 us-gaap Revenues
Revenues
1792000 USD
CY2015Q2 us-gaap Revenues
Revenues
376000 USD
CY2015Q3 us-gaap Revenues
Revenues
566000 USD
CY2015Q4 us-gaap Revenues
Revenues
127280000 USD
CY2015 us-gaap Revenues
Revenues
130014000 USD
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
7421000 USD
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
7081000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
6843000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4853635 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3842861 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
325000 USD
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
43000 USD
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
35000 USD
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.13
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.61
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.58
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10000000 USD
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2400000 USD
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
202073000 USD
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
318363000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
266678000 USD
CY2014Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7944133 shares
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
201947000 USD
CY2013 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1084000 USD
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
323000 USD
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
114000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
170163000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
284018000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
285850000 USD
CY2015 us-gaap Stockholders Equity Other
StockholdersEquityOther
70000 USD
CY2014Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
183000 shares
CY2015Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
237000 shares
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2390000 USD
CY2015Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2747000 USD
CY2013 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-873000 USD
CY2014 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-887000 USD
CY2015 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-357000 USD
CY2015Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2800000 USD
CY2013 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-21000 USD
CY2014 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-65000 USD
CY2015 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-156000 USD
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1200000 USD
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
103516000 shares
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
103608000 shares
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
103616000 shares
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115764000 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73302000 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73422000 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73518000 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73542000 shares
CY2014Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
84813000 shares
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
76347000 shares
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
103591000 shares
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103516000 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103608000 shares
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103616000 shares
CY2015Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
103623000 shares
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001062822-16-000051-index-headers.html Edgar Link pending
0001062822-16-000051-index.html Edgar Link pending
0001062822-16-000051.txt Edgar Link pending
0001062822-16-000051-xbrl.zip Edgar Link pending
exh1010non-employeedirecto.htm Edgar Link pending
exh1013noticeofnon-employe.htm Edgar Link pending
exh1014collaborationandlic.htm Edgar Link pending
exh108summaryofnon-employe.htm Edgar Link pending
exh109equityincentiveplan1.htm Edgar Link pending
exh231ernst_youngconsent10.htm Edgar Link pending
exh311certificationofprinc.htm Edgar Link pending
exh312certificationofprinc.htm Edgar Link pending
exh321certificationofprinc.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10k12312015.htm Edgar Link pending
image01.jpg Edgar Link pending
image02.jpg Edgar Link pending
image03.jpg Edgar Link pending
image04.jpg Edgar Link pending
image05.jpg Edgar Link pending
lxrx-20151231.xml Edgar Link completed
lxrx-20151231.xsd Edgar Link pending
lxrx-20151231_cal.xml Edgar Link unprocessable
lxrx-20151231_def.xml Edgar Link unprocessable
lxrx-20151231_lab.xml Edgar Link unprocessable
lxrx-20151231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending